Get the Daily Brief
Latest Biotech News
FDA Panel Recommends New RSV Antibody for Infants
The Advisory Committee on Immunization Practices (ACIP) voted 5-2 to endorse Merck’s RSV monoclonal antibody, Enflonsia, for infants during their first respiratory syncytial virus (RSV) season if...
Incyte Names Bill Meury as New CEO amid Strategic Transition
Incyte Corporation appointed Bill Meury as CEO following Hervé Hoppenot’s retirement after 11 years at the helm. Meury brings a track record of successful pharmaceutical leadership and dealmaking,...
Vor Biopharma Shifts Focus to Autoimmune Diseases with New Funding
Vor Biopharma has redirected its strategic focus from oncology to autoimmune disease following a significant private investment of $175 million and a $4.23 billion licensing deal for telitacicept...
Blood Test Innovation in Leukemia Risk Assessment
Researchers at the Weizmann Institute of Science have developed a novel minimally invasive blood test that detects early signs of leukemia risk by analyzing genetic alterations in hematopoietic...
AI-Powered TB Diagnostics Inspired by Beetle Chemistry
Scientists at Tulane University developed ASTRA, an innovative self-powered diagnostic device inspired by the bombardier beetle’s chemical defense mechanism, enhancing tuberculosis detection...
Clinical Progress and Funding in Neurology and Biopharma
Neuron23 advanced its clinical programs with a $96.5 million Series D funding round reflecting investor confidence in neurology therapeutics. Separately, Adaptive Biotechnologies experienced a...
Innovations in Hybrid Engineered Biological Systems
An interdisciplinary review in Nature Biotechnology classifies hybrid engineered biological systems that integrate biological components with electronics and microfluidics. These cyber-physical...
AI Models Enhance Cancer Imaging and Protein Drug Discovery
At Guangzhou Medical University, an AI model named NeoPred uses dual-phase CT and clinical data to predict lung cancer tumor response preoperatively, potentially refining treatment decisions....
Advances in Cell Therapy Manufacturing and Clinical Trials
Cidara Therapeutics completed a $402.5 million public offering to fund its Cloudbreak platform for developing drug-Fc conjugates. Ionis Pharmaceuticals and Biogen reported positive Phase 1 results...
Vor Bio's Strategic Pivot into Autoimmune Therapeutics
Vor Biopharma, after significant restructuring, secured $175 million in private equity and in-licensed telitacicept from China’s RemeGen. This dual-action fusion protein targets BAFF and APRIL...
New Study Illuminates PIEZO2’s Role in Heart Vessel Formation
Research led at Max Delbrück Center reveals PIEZO2 ion channels govern coronary vessel development in embryos, extending their known function beyond mechanosensation. Mouse models show both loss...
Plastic Waste Recycling via Inline Nuclear Magnetic Resonance
A novel solid-state NMR technique developed by a team at Dalian Institute of Chemical Physics utilizes 1H-13C FSLG-HETCOR spectroscopy to precisely characterize complex plastic waste mixtures....
Cutting-Edge Liver Organoids with Vascular Networks
Cincinnati Children’s Hospital researchers have engineered liver organoids capable of self-generating specialized blood vessels resembling human liver vasculature. Utilizing a multilayered gel...
Kymera’s oncology collaborations evolve with Gilead, Sanofi shifts focus
Kymera Therapeutics has entered a significant agreement with Gilead Sciences to jointly develop oral molecular glue degraders targeting CDK2 for solid tumors, including breast cancer. The deal...
DeepMind Unveils AlphaGenome to Model Gene Regulation from DNA
Google’s DeepMind has released AlphaGenome, an AI model designed to predict the effects of small DNA sequence changes on gene regulation. Building on the success of AlphaFold in protein structure...
Adaptive Biotechnologies Benefits from NCCN's Updated Multiple Myeloma Guidelines
Adaptive Biotechnologies’ stock surged following the National Comprehensive Cancer Network’s updated multiple myeloma guidelines, which now recommend baseline clonotype identification at diagnosis...
Gilead Ends RSV Antiviral Trials Citing Low Infection Rates
Gilead Sciences has terminated two Phase 2 trials of its RSV antiviral candidate obeldesivir due to lower-than-expected infection rates during the recent RSV season, which impaired the ability to...
Novartis and ProFound Therapeutics Partner on Cardiovascular Protein Targets
Novartis has signed a four-year strategic collaboration with ProFound Therapeutics, combinigng ProFound's advanced protein identification platform with Novartis’ cardiovascular expertise to...
Altimmune Posts Mixed Phase IIb Results in Fatty Liver Disease; Shares Plunge
Altimmune reported top-line data from its Phase IIb Impact study of pemvidutide, a GLP-1/glucagon dual receptor agonist, in metabolic dysfunction-associated steatohepatitis (MASH). The therapy met...
Mount Sinai Applies Wearable Tech to Link IBD Inflammation and Sleep Disruption
Researchers at Mount Sinai have utilized wearable devices such as smartwatches and fitness trackers in a longitudinal study to objectively measure sleep patterns in patients with inflammatory...